2212682
Project Grant
Overview
Grant Description
Sbir Phase I: Generation of Directly Active Monoclonal Antibodies to CD19 for the Treatment of B-Cell Malignancies -The Broader Impact /Commercial Potential of This Small Business Innovation Research (SBIR) Phase I Project Relates to Novel Monoclonal Antibody (MAB) Therapies for the Treatment of B-Cell Cancers (Leukemias and Lymphomas).
Current drugs for these cancers cause severe side effects, and patients overwhelmingly relapse. The reagents proposed here could be the first MABs to directly induce potent therapeutic effect in these diseases and are designed to be more tumor-specific than current therapies. Thus, the reagents offer the potential of a cure while minimizing the likelihood of side effects.
Well-tolerated and effective therapeutics are a known unmet need for these malignancies. Additionally, these directly active MABs could provide more affordable options than the engineered antibodies that have recently been approved. Research on these MABs will elucidate the relationship between structural elements of receptors and their function.
The success of these MABs will validate a novel drug-target discovery platform, which will be applied in developing antibodies to treat other cancers and autoimmune diseases. This Small Business Innovation Research (SBIR) Phase I project applies a drug discovery platform, focused on developing MABs to membrane receptors responsible for driving oncogenic signaling and malignant phenotypes.
These novel antibodies may induce direct biologic effects by interrupting cell-growth/survival pathways. One of the key players in controlling multiple activation pathways involved in cell survival and proliferation is CD19, which is ubiquitously expressed on B-cells and its dysregulation leads to B-cell malignancies.
Though CD19 has been used as a B-cell-specific drug target, no therapies exist that directly impact the signaling function of this receptor. This work has the potential to generate MABs to two selected epitopes on CD19. MABs that are specific and directly active will be further developed for clinical use.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Current drugs for these cancers cause severe side effects, and patients overwhelmingly relapse. The reagents proposed here could be the first MABs to directly induce potent therapeutic effect in these diseases and are designed to be more tumor-specific than current therapies. Thus, the reagents offer the potential of a cure while minimizing the likelihood of side effects.
Well-tolerated and effective therapeutics are a known unmet need for these malignancies. Additionally, these directly active MABs could provide more affordable options than the engineered antibodies that have recently been approved. Research on these MABs will elucidate the relationship between structural elements of receptors and their function.
The success of these MABs will validate a novel drug-target discovery platform, which will be applied in developing antibodies to treat other cancers and autoimmune diseases. This Small Business Innovation Research (SBIR) Phase I project applies a drug discovery platform, focused on developing MABs to membrane receptors responsible for driving oncogenic signaling and malignant phenotypes.
These novel antibodies may induce direct biologic effects by interrupting cell-growth/survival pathways. One of the key players in controlling multiple activation pathways involved in cell survival and proliferation is CD19, which is ubiquitously expressed on B-cells and its dysregulation leads to B-cell malignancies.
Though CD19 has been used as a B-cell-specific drug target, no therapies exist that directly impact the signaling function of this receptor. This work has the potential to generate MABs to two selected epitopes on CD19. MABs that are specific and directly active will be further developed for clinical use.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Briarcliff Manor,
New York
10510-1955
United States
Geographic Scope
Single Zip Code
Related Opportunity
None
Welt Bio-Molecular Pharmaceutical was awarded
Project Grant 2212682
worth $256,000
from National Science Foundation in February 2023 with work to be completed primarily in Briarcliff Manor New York United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I:Generation of directly active monoclonal antibodies to CD19 for the treatment of B-cell malignancies
Abstract
The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project relates to novel monoclonal antibody (mAb) therapies for the treatment of B-cell cancers (leukemias and lymphomas). Current drugs for these cancers cause severe side effects, and patients overwhelmingly relapse. The reagents proposed here could be the first mAbs to directly induce potent therapeutic effect in these diseases and are designed to be more tumor-specific than current therapies. Thus, the reagents offer the potential of a cure while minimizing the likelihood of side effects. Well-tolerated and effective therapeutics are a known unmet need for these malignancies. Additionally, these directly active mAbs could provide more affordable options than the engineered antibodies that have recently been approved. Research on these mAbs will elucidate the relationship between structural elements of receptors and their function.The success of these mAbs will validate a novel drug-target discovery platform, which will be applied in developing antibodies to treat other cancers and autoimmune diseases. _x000D_ _x000D_ This Small Business Innovation Research (SBIR) Phase I project applies a drug discovery platform, focused on developing mAbs to membrane receptors responsible for driving oncogenic signaling and malignant phenotypes. These novel antibodies may induce direct biologic effects by interrupting cell-growth/survival pathways. One of the key players in controlling multiple activation pathways involved in cell survival and proliferation is CD19, which is ubiquitously expressed on B-cells and its dysregulation leads to B-cell malignancies. Though CD19 has been used as a B-cell-specific drug target, no therapies exist that directly impact the signaling function of this receptor. This work has the potential to generate mAbs to two selected epitopes on CD19. mAbs that are specific and directly active will be further developed for clinical use._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
PT
Solicitation Number
NSF 21-562
Status
(Complete)
Last Modified 2/6/23
Period of Performance
2/1/23
Start Date
1/31/24
End Date
Funding Split
$256.0K
Federal Obligation
$0.0
Non-Federal Obligation
$256.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2212682
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
Q9NEYZLBH5G3
Awardee CAGE
502Z1
Performance District
Not Applicable
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $256,000 | 100% |
Modified: 2/6/23